Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Perspective Therapeutics (CATX) Non Operating Income (2016 - 2025)

Perspective Therapeutics' Non Operating Income history spans 15 years, with the latest figure at -$7.7 million for Q4 2024.

  • For Q4 2024, Non Operating Income fell 865.21% year-over-year to -$7.7 million; the TTM value through Sep 2024 reached $6.9 million, up 636.62%, while the annual FY2022 figure was $618000.0, N/A changed from the prior year.
  • Non Operating Income for Q4 2024 was -$7.7 million at Perspective Therapeutics, down from $3.5 million in the prior quarter.
  • Across five years, Non Operating Income topped out at $3.5 million in Q3 2024 and bottomed at -$7.7 million in Q4 2024.
  • The 5-year median for Non Operating Income is $28500.0 (2022), against an average of $6888.9.
  • The largest YoY upside for Non Operating Income was 3000.0% in 2021 against a maximum downside of 2800.0% in 2021.
  • A 5-year view of Non Operating Income shows it stood at $5000.0 in 2020, then plummeted by 2800.0% to -$135000.0 in 2021, then soared by 203.7% to $140000.0 in 2022, then plummeted by 672.86% to -$802000.0 in 2023, then tumbled by 865.21% to -$7.7 million in 2024.
  • Per Business Quant, the three most recent readings for CATX's Non Operating Income are -$7.7 million (Q4 2024), $3.5 million (Q3 2024), and $3.0 million (Q2 2024).